Traditional Antiplatelet Therapy Control Group — Competitive Intelligence Brief

Traditional Antiplatelet Therapy Control Group (Traditional Antiplatelet Therapy Control Group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent. Area: Cardiovascular.

marketed Antiplatelet agent Cardiovascular Small molecule

Target snapshot

Traditional Antiplatelet Therapy Control Group (Traditional Antiplatelet Therapy Control Group) — Sichuan Provincial People's Hospital. Traditional antiplatelet therapy inhibits platelet aggregation through multiple pathways to reduce thrombotic events.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Traditional Antiplatelet Therapy Control Group TARGET	Traditional Antiplatelet Therapy Control Group	Sichuan Provincial People's Hospital	marketed	Antiplatelet agent
Plavix	clopidogrel	Generic (originally Sanofi/BMS)	marketed	Thienopyridine antiplatelet agent	Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter	1997-11-17
Aspirin	acetylsalicylic acid	Bayer AG	marketed	NSAID, Antiplatelet agent	Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3	1899-03-06
aspirin (ASA)	aspirin (ASA)	Janssen Scientific Affairs, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Aspirin and clopidogrel / Prasugrel	Aspirin and clopidogrel / Prasugrel	Assistance Publique - Hôpitaux de Paris	marketed	Antiplatelet agent (dual therapy combination)	COX-1 (aspirin); P2Y12 receptor (clopidogrel/prasugrel)
Chewing Ticagrelor LD	Chewing Ticagrelor LD	Sheba Medical Center	marketed	P2Y12 receptor antagonist (antiplatelet agent)	P2Y12 receptor
ticagrelor + ASA	ticagrelor + ASA	Peking University Third Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent class)

1. Asan Medical Center · 1 drug in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
5. China National Center for Cardiovascular Diseases · 1 drug in this class
6. Hospital Israelita Albert Einstein · 1 drug in this class
7. Icahn School of Medicine at Mount Sinai · 1 drug in this class
8. PLx Pharma · 1 drug in this class
9. Sichuan Provincial People's Hospital · 1 drug in this class
10. The George Institute for Global Health, China · 1 drug in this class